[go: up one dir, main page]

HRP20161348T1 - Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije - Google Patents

Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije Download PDF

Info

Publication number
HRP20161348T1
HRP20161348T1 HRP20161348TT HRP20161348T HRP20161348T1 HR P20161348 T1 HRP20161348 T1 HR P20161348T1 HR P20161348T T HRP20161348T T HR P20161348TT HR P20161348 T HRP20161348 T HR P20161348T HR P20161348 T1 HRP20161348 T1 HR P20161348T1
Authority
HR
Croatia
Prior art keywords
substance
deuterium
image
atom
treatment
Prior art date
Application number
HRP20161348TT
Other languages
English (en)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Klaus Gjervig Jensen
Mette Graulund Hvenegaard
Lassina Badolo
Mikkel Fog Jacobsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20161348T1 publication Critical patent/HRP20161348T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (31)

1. Tvar formule Y [image] pri čemu R1-R10 su nezavisno vodik ili deuterij, pri čemu su R6-R10 svaki deuterij, pri čemu najmanje jedan od R1-R10 sadrži najmanje oko 50% deuterija, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline.
2. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R3-R5 vodik.
3. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R3-R5 deuterij.
4. Tvar iz patentnog zahtjeva 2, pri čemu je tvar [image]
5. Tvar iz patentnog zahtjeva 2, pri čemu je tvar [image]
6. Tvar iz patentnog zahtjeva 3, pri čemu je tvar [image]
7. Tvar iz patentnog zahtjeva 3, pri čemu je tvar [image]
8. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R1 i R2deuterij.
9. Tvar iz patentnog zahtjeva 8, pri čemu je svaki od R3-R5 deuterij.
10. Tvar iz patentnog zahtjeva 8, pri čemu je svaki od R3-R5 vodik.
11. Tvar iz bilo kojeg od patentnih zahtjeva 1-10, pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
12. Tvar iz bilo kojeg od patentnih zahtjeva 1-11, pri čemu najmanje oko 90% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
13. Tvar iz patentnog zahtjeva 1, pri čemu je tvar hidrogen tartaratna sol tvari [image]
14. Tvar iz patentnog zahtjeva 13, pri čemu tvar postoji u polimorfnom obliku i ima XRPD uzorak difrakcije kako je prikazano na Slici 18.
15. Tvar iz patentnog zahtjeva 13, pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
16. Farmaceutski sastav obuhvaća tvar iz bilo kojeg od patentnih zahtjeva 1 do 15 i jedan ili više farmaceutski prihvatljivih nosača, diluenata, ili ekscipijenasa.
17. Farmaceutski sastav iz patentnog zahtjeva 16, pri čemu je tvar hidrogen tartaratna sol tvari [image]
18. Tvar iz patentnih zahtjeva 16 ili 17, pri čemu nosač sadrži hidroksipropil-β-ciklodekstrin u vodi i pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
19. Uporaba tvari iz bilo kojeg od patentnih zahtjeva 1-15, ili sastava iz bilo kojeg od patentnih zahtjeva 16-18 za proizvodnju lijeka za liječenje psihoza, drugih bolesti koje uključuju psihotične simptome, psihotičke poremećaje ili bolesti koje se manifestiraju psihotičnim simptomima.
20. Uporaba u skladu s patentnim zahtjevom 19, pri čemu su psihoze ili bolesti koje uključuju psihotične simptome shizofrenija, shizofrenoformni poremećaj, shizoafektivni poremećaj, diluzijski poremećaj, kratkotrajni psihotički poremećaj, grupni psihotički poremećaj, bipolarni poremećaj, ili manija u bipolarnom poremećaju.
21. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, nadalje obuhvaća tvar odabranu iz grupe koja sadrži sertindol, olanzapin, risperidon, kvetiapin, aripiprazol, haloperidol, klozapin, ziprasidon i osanetant.
22. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, pri čemu je psihoza ili bolest koja uključuje psihotične simptome shizofrenija.
23. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, pri čemu je psihoza ili bolest koja uključuje psihotične simptome shizofrenija, pri čemu farmaceutski sastav sadrži učinkovitu količinu hidrogen tartaratne soli tvari [image] i hidroksipropil-β-ciklodekstrin u vodi i pri čemu najmanje oko 85% tvari (IV) ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
24. Tvar formule [image]
25. Postupak za pripravu tvari [image] obuhvaća tretiranje tvari (XIV) sa [(S)-BINAP]Rh(I)BF4. [image]
26. Postupak iz patentnog zahtjeva 25, pri čemu se [(S)-BINAP]Rh(I)BF4 koristi u katalitičkoj količini.
27. Postupak za pripravu tvari (XIV) obuhvaća a) tretiranje [image] s bis(pinakolato)diboronom, i b) tretiranje s 2-bromo-5-klorobenzaldehidom.
28. Postupak iz patentnog zahtjeva 27, pri čemu tretiranje tvari [image] s bis(pinakolato)diboronom nadalje uključuje dodavanje Pd(II).
29. Postupak iz patentnog zahtjeva 28, pri čemu tretiranje s 2-bromo-5-klorobenzaldehidom nadalje uključuje dodavanje Pd(0).
30. Postupak priprave tvari (1R, 3S)-(IV) tartarata obuhvaća tretiranje racemičnog trans-1-(6-kloro-3-fenil(d5)-indan-1-il)-1(d3),2,2-trimetil-piperazina s L-(+)-vinskom kiselinom.
31. Postupak iz patentnog zahtjeva 30, pri čemu se racemični trans-1-(6-kloro-3-fenil(d5)-indan-1-il)-1(d3),2,2-trimetil-piperazin stvara iz njegove odgovarajuće sukcinatne soli.
HRP20161348TT 2011-06-20 2016-10-17 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije HRP20161348T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
PCT/IB2012/001386 WO2012176066A1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
EP12748046.5A EP2720989B1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
HRP20161348T1 true HRP20161348T1 (hr) 2016-12-02

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161348TT HRP20161348T1 (hr) 2011-06-20 2016-10-17 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije
HRP20190593TT HRP20190593T1 (hr) 2011-06-20 2019-03-27 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190593TT HRP20190593T1 (hr) 2011-06-20 2019-03-27 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije

Country Status (41)

Country Link
US (8) US8575174B2 (hr)
EP (4) EP2720989B1 (hr)
JP (1) JP5668177B2 (hr)
KR (2) KR101939546B1 (hr)
CN (1) CN103649019B (hr)
AP (1) AP3310A (hr)
AR (1) AR086987A1 (hr)
AU (1) AU2012273657B2 (hr)
BR (1) BR112013031702B1 (hr)
CA (1) CA2837820C (hr)
CL (1) CL2013003646A1 (hr)
CO (1) CO6821965A2 (hr)
CR (1) CR20130654A (hr)
CY (2) CY1118158T1 (hr)
DK (2) DK3135656T3 (hr)
DO (1) DOP2013000305A (hr)
EA (1) EA024651B1 (hr)
EC (1) ECSP14013155A (hr)
ES (3) ES2939477T3 (hr)
GE (1) GEP201706655B (hr)
GT (1) GT201300304A (hr)
HK (1) HK1197228A1 (hr)
HR (2) HRP20161348T1 (hr)
HU (2) HUE030883T2 (hr)
IL (1) IL229640B (hr)
JO (1) JO3128B1 (hr)
LT (2) LT2720989T (hr)
MA (1) MA35268B1 (hr)
MD (1) MD4538C1 (hr)
ME (2) ME03375B (hr)
MX (1) MX339552B (hr)
MY (1) MY196998A (hr)
PE (2) PE20141113A1 (hr)
PH (1) PH12013502598A1 (hr)
PL (2) PL3135656T3 (hr)
PT (2) PT3135656T (hr)
RS (2) RS58546B1 (hr)
SI (2) SI3135656T1 (hr)
SM (2) SMT201900179T1 (hr)
TW (3) TWI614234B (hr)
WO (1) WO2012176066A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03375B (me) 2011-06-20 2020-01-20 H Lundbeck As Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
PT3679018T (pt) 2017-09-07 2022-04-05 Otsuka Pharma Co Ltd Processo industrial de monoalquilação de um nitrogénio de piperidina em derivados de piperidina com alquilo deuterado
WO2020089147A1 (en) * 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
EA202191731A1 (ru) * 2018-12-21 2021-10-28 Консерт Фармасьютикалз, Инк. Дейтерированные формы и производные волинансерина
CA3132953A1 (en) * 2019-03-13 2020-09-17 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196284A (en) 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
AU599580B2 (en) 1984-12-04 1990-07-26 Sandoz Ag Indene analogs of mevalonolactone
WO2010037398A1 (en) 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2536144C (en) 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
RS20060083A (en) * 2003-08-18 2008-08-07 H.Lundbeck A/S., Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
CA2597620A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
BRPI0615973A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc novos derivados de benzo [d] [1,3] - dioxol
JP5302005B2 (ja) 2005-12-01 2013-10-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド セロトニン作動性および／またはノルエピネフリン作動性の活性を有する置換フェネチルアミン
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
PT2003120E (pt) 2007-06-12 2010-02-11 Concert Pharmaceuticals Inc Derivados de azapéptido como inibidores de protease de hiv
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
EA018927B1 (ru) 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
KR20110110097A (ko) 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
EP2362865A2 (en) 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2639216B1 (en) 2010-11-09 2018-07-11 Kaneka Corporation Halogenated indenones and method for producing optically active indanones or optically active indanols by using same
JP2014501771A (ja) 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
CN109608436B (zh) 2011-04-08 2022-10-11 斯法尔制药私人有限公司 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法
ME03375B (me) 2011-06-20 2020-01-20 H Lundbeck As Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije
WO2014055938A1 (en) 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
EP3135656B1 (en) 2019-02-27
ES2719145T3 (es) 2019-07-08
BR112013031702B1 (pt) 2021-11-03
JP2014520140A (ja) 2014-08-21
HUE044043T2 (hu) 2019-09-30
US12116355B2 (en) 2024-10-15
CR20130654A (es) 2014-03-24
WO2012176066A1 (en) 2012-12-27
AP2013007338A0 (en) 2013-12-31
US20150307458A1 (en) 2015-10-29
PT3135656T (pt) 2019-05-03
HK1197228A1 (zh) 2015-01-09
TW201311248A (zh) 2013-03-16
SI3135656T1 (sl) 2019-05-31
MX339552B (es) 2016-05-31
US10501427B2 (en) 2019-12-10
US10118907B2 (en) 2018-11-06
CY1121514T1 (el) 2020-05-29
PT2720989T (pt) 2016-11-07
CA2837820A1 (en) 2012-12-27
EA024651B1 (ru) 2016-10-31
DK2720989T3 (en) 2016-11-28
US9216961B2 (en) 2015-12-22
US20190031631A1 (en) 2019-01-31
DK3135656T3 (en) 2019-04-23
AU2012273657A1 (en) 2013-12-12
CA2837820C (en) 2019-02-19
PE20141113A1 (es) 2014-09-25
ME02513B (me) 2017-02-20
JO3128B1 (ar) 2017-09-20
MA35268B1 (fr) 2014-07-03
EP3508468A1 (en) 2019-07-10
IL229640A0 (en) 2014-01-30
ME03375B (me) 2020-01-20
HUE030883T2 (en) 2017-06-28
HRP20190593T1 (hr) 2019-05-17
ECSP14013155A (es) 2014-02-28
RS55304B1 (sr) 2017-03-31
US20120322811A1 (en) 2012-12-20
RS58546B1 (sr) 2019-05-31
US9012453B2 (en) 2015-04-21
BR112013031702A2 (pt) 2016-12-13
US11059798B2 (en) 2021-07-13
CY1118158T1 (el) 2017-06-28
MD20140004A2 (en) 2014-05-31
TW201902481A (zh) 2019-01-16
AR086987A1 (es) 2014-02-05
LT3135656T (lt) 2019-04-25
IL229640B (en) 2018-02-28
EP3135656A1 (en) 2017-03-01
KR20180075717A (ko) 2018-07-04
SI2720989T1 (sl) 2016-11-30
GT201300304A (es) 2015-01-16
EP4215512A1 (en) 2023-07-26
KR101879474B1 (ko) 2018-07-17
EP2720989B1 (en) 2016-08-10
TW201722895A (zh) 2017-07-01
TWI627956B (zh) 2018-07-01
US8575174B2 (en) 2013-11-05
MD4538C1 (ro) 2018-07-31
NZ618222A (en) 2015-03-27
ES2601213T3 (es) 2017-02-14
US20130281436A1 (en) 2013-10-24
US9617231B2 (en) 2017-04-11
KR20140041567A (ko) 2014-04-04
AU2012273657B2 (en) 2016-07-21
EP2720989A1 (en) 2014-04-23
PE20150928A1 (es) 2015-06-26
US20220119362A1 (en) 2022-04-21
KR101939546B1 (ko) 2019-01-16
JP5668177B2 (ja) 2015-02-12
PL2720989T3 (pl) 2017-05-31
EP3508468B1 (en) 2023-01-18
PL3135656T3 (pl) 2019-07-31
SMT201600383B (it) 2017-01-10
TWI659741B (zh) 2019-05-21
TWI614234B (zh) 2018-02-11
US20160068497A1 (en) 2016-03-10
US20170158650A1 (en) 2017-06-08
SMT201900179T1 (it) 2019-05-10
DOP2013000305A (es) 2014-02-28
MD4538B1 (ro) 2017-12-31
GEP201706655B (en) 2017-04-25
LT2720989T (lt) 2016-11-25
CO6821965A2 (es) 2013-12-31
MX2013014849A (es) 2014-03-31
CN103649019A (zh) 2014-03-19
ES2939477T3 (es) 2023-04-24
EA201490045A1 (ru) 2014-07-30
PH12013502598A1 (en) 2014-02-10
MY196998A (en) 2023-05-17
CN103649019B (zh) 2015-09-16
AP3310A (en) 2015-06-30
US20200131143A1 (en) 2020-04-30
CL2013003646A1 (es) 2014-07-04

Similar Documents

Publication Publication Date Title
HRP20161348T1 (hr) Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije
DOP2013000194A (es) Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos
JP2014520140A5 (hr)
HRP20110206T1 (hr) Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti
JP2015505296A5 (hr)
BR112014010263A2 (pt) método de preparação do acetato de ulipristal e intermediário deste
ME02749B (me) Deuterisani derivati ivakaftora
CA3025586A1 (en) Pde9 inhibitors for treatment of peripheral diseases
HRP20140336T1 (hr) Inhibitori glicin transportera-1
NZ600416A (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
ECSP13012852A (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a.
JP2014524936A5 (hr)
JP2013542963A5 (hr)
JP2012519182A5 (hr)
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
NZ614567A (en) Novel compounds as histamine h3 receptor ligands
HRP20130234T1 (hr) Derivat dibenzotiazepina i njegova uporaba
CN102260290A (zh) 喹喏啉酮类化合物及其在制备精神病药物中的用途
HRP20161167T1 (hr) Spoj akrilamida kao ligandi histaminskog h3 receptora
RU2014119929A (ru) КИСЛОТНО-АДДИТИВНЫЕ СОЛИ 5α-ГИДРОКСИ-6β-[2-(1H-ИМИДАЗОЛ-4-ИЛ)ЭТИЛАМИНО]ХОЛЕСТАН-3β-ОЛА
CN102267971B (zh) 脂环并[c]苯并吡喃酮衍生物及其应用
WO2013166276A4 (en) Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
CN102826994A (zh) 一种莽草酸的制备方法
CN102225906B (zh) 一种沃尼妙林盐酸盐的结晶方法
CN103351361B (zh) 左旋西替利嗪及其二盐酸盐的制备方法